All In Biotech

Drug Trial Radar · NCT05844423

Safety, Tolerability, and Immunogenicity of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Healthy Infants

Randomized, Observer-Blind, Active-Controlled, Dose-Finding Study to Evaluate the Safety, Tolerability, and Immunogenicity of 24-Valent PCV (VAX-24) in Infants Given 4 Doses at 2, 4, 6, and 12-15 Months of Age With Pediatric Vaccines

Last checked: Nov 19, 2026Latest source record: Sep 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 802 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

802

Actual

Start

Mar 29, 2023

Primary completion

Aug 25, 2025

Study completion Aug 25, 2025

Sponsor

Lead sponsor
Vaxcyte, Inc.Industry
Sponsor type
Industry
First posted
May 6, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 42 days, up to 89 days
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The objective of the study is to evaluate the safety and tolerability of 4 injections of VAX-24 (at 3 dose levels) compared to PCV15 in infants at 2, 4, 6, and 12-15 months of age, in addition to receiving routine US concomitant vaccines. Stage 1 of the study will comprise 3 dose ascending cohorts. Stage 2 of the study will enroll the remainder of the sample size.

Conditions

  • Pneumococcal Vaccines

Interventions

  • 0.5 ml dose of 1.1 mcg VAX-24Biological

    24 valent pneumococcal conjugate vaccine

  • 0.5 ml dose of PCV20Biological

    20 valent pneumococcal conjugate vaccine

  • 0.5 ml dose of 2.2 mcg VAX-24Biological

    24 valent pneumococcal conjugate vaccine

  • 0.5 ml dose of 2.2/4.4 mcg VAX-24Biological

    24 valent pneumococcal conjugate vaccine

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of participants with any solicited local injection site Adverse Events (AE) within 7 days after each vaccinationTime frame: 7 days after each vaccination
  2. Percentage of participants with any solicited systemic AE within 7 days after each vaccinationTime frame: 7 days after each vaccination
  3. Percentage of participants with any related Serious Adverse Events (SAE) within 6 months after last vaccinationTime frame: 6 months after last vaccination

Locations

32 sites in 1 country. Site status is shown where the registry gives one.

  • The Children's Clinic of Jonesboro, P.A.

    Jonesboro, Arkansas

  • Madera Family Medical Group

    Madera, California

  • Jedidiah Clinical Research

    Tampa, Florida

  • Kentucky Pediatric/ Adult Research

    Bardstown, Kentucky

  • ACC Pediatric Research

    Haughton, Louisiana

  • Meridian Clinical Research

    Hastings, Nebraska

  • Midwest Children's Health Research Institute

    Lincoln, Nebraska

  • Midwest Children's Health Research Institute

    Lincoln, Nebraska

  • Midwest Children's Health Research Institute

    Lincoln, Nebraska

  • Midwest Children's Health Research Institute

    Lincoln, Nebraska

  • Ohio Pediatric Research Assn.

    Dayton, Ohio

  • UPMC Bass Wolfson Cranberry

    Cranberry Township, Pennsylvania

  • Allegheny Health and Wellness Pavilion

    Erie, Pennsylvania

  • UPMC Children's Community Pediatrics South Hills-Jefferson Hills

    Jefferson Hills, Pennsylvania

  • UPMC Primary Care Center Oakland

    Pittsburgh, Pennsylvania

  • UPMC Children's Community Pediatrics Bass Wolfson-Squirrel Hill

    Pittsburgh, Pennsylvania

  • UPMC Children's Community Pediatrics-Castle Shannon

    Pittsburgh, Pennsylvania

  • Palmetto Pediatrics, PA

    North Charleston, South Carolina

  • Tribe Clinical Research at Parkside Pediatrics

    Simpsonville, South Carolina

  • Coastal Pediatric Research

    Summerville, South Carolina

  • Holston Medical Group

    Kingsport, Tennessee

  • Ventavia Research Group

    Burleson, Texas

  • Ventavia

    Houston, Texas

  • Kool Kids Pediatrics

    Houston, Texas

  • Pediatric Associates

    Houston, Texas

  • Pediatric Center

    Richmond, Texas

  • Alliance for Multispecialty Research

    Layton, Utah

  • Alliance for Multispecialty Research

    Murray, Utah

  • Alliance for Multispecialty Research

    Provo, Utah

  • Alliance for Multispecialty Research

    Roy, Utah

  • Alliance for Multispecialty Research

    Syracuse, Utah

  • Pediatric Research of Charlottesville, LLC

    Charlottesville, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.